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ABSTRACT
The inclusion of racial/ethnic minorities in treatment outcomes trials for children and
adolescents with depression and anxiety is essential, particularly given the assumption,
required by the NIH, that racial diversity is important to the generalizability of clinical
trial outcomes. A search for randomized clinical trials on the treatment of child and
adolescent depression and anxiety was conducted using the Medline and Psychinfo
databases. These were then reviewed to determine whether race or ethnicity were 1)
factored into recruitment strategies; 2) represented in the trial sample; and 3) included in
moderator analyses to determine the extent to which they may influence trial outcomes.
37 original and 13 follow-up trials were identified (total N = 3330). None identified
strategies for targeted recruitment of racial/ethnic minorities. Six did not report race. All
minority groups except for Native Americans are underrepresented as compared to 2000
US Census figures; however, only one study reported Native Americans as participants.
Overall, 67% of the sample was Caucasian, 26% minority, and 6% unreported. There
was no trend in minority representation by year. Most studies reviewed do report the
ethnic breakdown of their sample population, although methods vary. Six studies, three
original and three follow-up, explored the ethnicity as a moderator. Without an increased
presence of minorities in clinical trials, it is unclear that the results of these studies can
reliably generalize to a diverse population. The importance of studies in minority
samples becomes apparent, as does the need for a greater emphasis on recruitment.
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INTRODUCTION
Depression
Depression is, according to the World Health Organization (WHO), “the leading cause of
disability as measured by YLDs 1 and the 4th leading contributor to the global burden of
disease (DALYs 2 ) in 2000.” [1] Perhaps even more worrisome, studies seem to indicate
that the presentation of depression during childhood or adolescence is common, often
chronic, and associated with high levels of morbidity and mortality from suicide. [2] The
National Comorbidity Study, while it did not focus exclusively on children and
adolescents, found the highest 30-day prevalence in the youngest age group studied, 1524 year olds. [2] In a 10-year review of depression, Birmaher et al. report that the
estimated lifetime prevalence of depression in adolescents ranges from 15% to 20%. [3]
It is also noted that the suicide rate for teenagers has increased rapidly in the latter part of
the 20th century, quadrupling since 1950. This rapid rise also holds true for AfricanAmericans, especially in more recent years. According to the Centers for Disease
Control (CDC), African-American males aged 15-19 experienced a 146% increase in
suicide rate between 1980 and 1995. [4] In a study of suicide in over 1,000
predominantly poor African-American adolescents, Iolongo et al. found the lifetime
prevalence of suicidal ideation to be 5.3%. [5] A 2004 study reported that lifetime
prevalence of major depressive disorder was 9.4% in a demographically similar
population. [6]
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Although the exact causes and/or mechanisms of depression are unclear, the possibility of
a genetic component to the disease remains. Birmaher et al. report that children who
grow up with at least one depressed parent are much more likely to experience an episode
of major depression in their lifetime. [3]

Anxiety
Anxiety disorders, the most common mental health disorders, similarly affect populations
worldwide. “Anxiety disorders not only are common in the United States, but they are
ubiquitous across human cultures.” [7] Among adults in the United States aged 18-54, the
estimated 1-year prevalence is over 16%. [7] As with major depressive disorder, there is
significant chronicity and morbidity associated with anxiety disorders. Some studies
have found anxiety disorders, specifically panic disorder, to be linked to suicide attempts.
[8] Again, as with depression, anxiety disorders appear to be common in children and
adolescents. Various studies of anxiety disorders report that prevalence can range from
5.7% to 17.7%. In a 21-year longitudinal study of almost 1000 children from New
Zealand, Woodward and Fergusson found the presence of an anxiety disorder in
adolescence to be associated with a number of later negative outcomes. These include
later mental health problems (including suicide), drug use, and “educational
underachievement.” [9]

Treatment Options
In the 1980’s, the number of randomized controlled trials exploring possible treatment
options for children and adolescents with depression and anxiety began to rise steeply.

However, a larger amount of clinical trials looking into the safety and efficacy of
treatment options in depression and anxiety have been directed at adults. Despite this,
pharmacologic as well as therapeutic treatment of young people with depression has been
widespread. It is unclear whether results from adult populations can, or should, be
extrapolated to include children and adolescents. In addition, the effectiveness of some
of these treatment options, especially for young people, has yet to be established. One
recent study [10], for example, found that although clinical trials have proven cognitivebehavioral therapy to be efficacious in the treatment of youth with depression,
community clinic treatment of young people with depression has not proven to be as
beneficial for patients, with results comparable to no treatment at all. These issues have
become more controversial given the recent questions surrounding the safety and efficacy
of SSRI use in children and the “black box” warning labels now required on such
medications.

Treatment-Seeking
Many people, children and adults alike, do not seek treatment for mood disorders. As
noted by the Surgeon General in the 1999 Report on Mental Health, “nearly two-thirds of
all people with diagnosable mental disorders do not seek treatment.” [11] Of those that
do, many seek care from primary care practitioners rather than specialists in the field.
One of the most significant reasons for this lack of treatment-seeking and utilization of
specialists is the role of stigma in mental health care, which the Surgeon General’s office
reports may be linked with fear of the violence can be associated with mental health
disorders. [11] However, there may be other issues at play. One study, for example,

found that while the utilization of mental health services in San Francisco’s Chinatown
was minimal, this was more likely to be due to a decreased level of acculturation, and
lack of information about available services, than stigma. [12]

The role that demographic factors such as race or ethnicity may play in treatment-seeking
behavior is somewhat unclear. In 1987, Sussman et al. [13] found the proportion of
African-Americans fearing mental health treatment to be 2.5 times higher than White
patients. When examining attitudes towards ADHD and its treatment, Bussing et al.
found that African-American parents of children meeting ADHD criteria were less likely
to use medical labels than White parents. [14] African-American parents also expected a
shorter course of treatment. It has been reported that African-Americans are less likely
than Caucasians to visit mental health professions. [15] While there are differences in
insurance rates between Blacks and Whites, it has been found that the possession of
above-average mental health coverage increases treatment-seeking among Caucasian
patients more than in African-Americans. [16] In a study of the Epidemiologic
Catchment Area Program, Gallo et al. also found that White Americans were
significantly more likely to have consulted a mental health specialist in the 6 months
prior to the interview than African-Americans, Hispanics, and other minority groups. [17]
However, other recent research has stated that Latino patients, while less likely to
approve of antidepressant medications, are also more likely to support counseling than
Caucasians or African-Americans. [18] In a follow-up study to one initially conducted in
1981, Cooper-Patrick et al. reported that while at baseline African-Americans were
initially less likely than Caucasians to receive mental health services, use among African-

Americans patients increased over the 1980’s. [19] By follow-up in the mid 1990’s,
Black patients were as likely to utilize mental health services offered in general
practitioner offices as White patients. While there has been much research on treatmentseeking behavior in mental health, it is clear that continuing study is called for, especially
as pertains to children and adolescents.

Health Disparities
The IOM report on disparities, “Racial and Ethnic Disparities in Health Care,” found that
many health disparities exist, in a variety of medical specialties. African-Americans in
the United States have higher mortality rates. This is especially striking in the case of
African-American males as well as in infant mortality, which for Black patients is twice
that of Caucasians in this country. A significant difference in infant mortality exists even
when other socioeconomic factors, such as income, are controlled for. [15] It has been
shown that African-Americans, in particular, suffer from higher rates of various diseases,
with poorer outcomes. Black patients also suffer from higher morbidity rates in diabetes
(three times that of White patients), heart disease (40% higher), HIV/AIDS (seven times
higher), prostate cancer (twice as high), and even breast cancer, despite the fact that more
African-American women undergo screening by mammography. [15]

The IOM report also looked into possible explanations for these various differences in
health outcomes. The authors examined over 100 studies in the area of health disparities,
and discovered that even when controlling for other demographic factors such as income,
age, insurance status and education level, a majority of the studies found that racial and

ethnic minorities were less likely to “receive needed services, including clinically
necessary procedures.” [20]. The report hypothesizes that one possible reason that racial
and ethnic minorities receive lower quality health care than White patients is due to a
subconscious racial bias that physicians may possess. It also cites various studies that,
for example, have shown that doctors, when presented with the same written description
of a patient’s case except for the race of the patient, have offered treatment
recommendations that differed.

Of particular relevance to this review, it has also been found that ethnic minorities
receive substandard mental health care. [11, 21] In addition, the increased amount of fear
of mental health treatment amongst African-American adults mentioned earlier [13] is
likely related to the fact that African-Americans have been found to have increased rates
of involuntary hospitalization when compared to Caucasian patients with similar
psychopathology levels. [22] Among young people in particular, African-American
children have been found to be more likely to have “unmet need 3 ” than Caucasian
children. [15] Some studies have reported higher rates of certain mental health disorders
such as obsessive-compulsive disorder and conduct disorder, along with depressive
symptomology and enuresis, among minority children. Also of note is that 42% of
children in foster care have been found to meet DSM-IV criteria for a mental health
disorder. [23] Minority children are over-represented in the foster care/child welfare
system.
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Attitudes toward medicine/research
Studies have been done relating race and/or ethnicity to attitudes towards the medical
profession in general, with African-American adults being more likely to distrust doctors
[24], including those running clinical trials. [25] Black patients are more likely to have
heard of the Tuskegee syphilis experiment 4 than White patients. [25, 26] This lack of
trust in the medical profession may contribute to researchers experiencing increased
difficulty when attempting to recruiting minority patients into medical trials, in particular
when there are no directed attempts at minority outreach. For adults with depression,
race/ethnicity, in particular, has been found to be significantly correlated with treatmentseeking, the acceptability of certain kinds of treatments over others, and also the clinical
setting in which depressed patients are most likely to seek help. Minority patients have
been found to be more likely to visit primary care practitioners or emergency rooms than
mental health professionals. [27] African-Americans have also been found to be
significantly more likely to exclusively consult friends and/or family members about
mental health issues, rather than doctors or other healthcare providers. [27] Attitudes
towards the health profession in general, and mental health practitioners specifically, may
affect patients’ decisions about participating in clinical trials, seeking help, or even the
effectiveness of therapy or other treatments.

NIH Revitalization Act of 1993
The number of randomized controlled clinical trials testing the efficacy and effectiveness
of both pharmaceutical and therapeutic treatments is on the rise. However, the
4
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generalizability of these trials, based on demographic factors including race and/or
ethnicity, is an important issue, one that the United States government as well as the
National Institutes of Health (NIH) have acknowledged. This is especially true given the
existence of a multitude of health disparities, and the lack of clear rationale for these
inconsistencies in health and health care.

The NIH Revitalization Act, signed into law by President Clinton in 1993, directed the
National Institutes of Health to create a set of guidelines for the inclusion of women and
racial/ethnic minorities in clinical research. The purpose of the proposed guidelines was
to supplement existing guidelines in four ways; by ensuring that 1) women and racial
minorities were included in clinical research, 2) cost would not be permissible as a factor
in excluding women and minorities, 3) the NIH would start and assist in outreach efforts
for women and minorities in studies, and finally that 4) clinical trials would be
…designed and carried out in a manner sufficient to provide for valid
analysis of whether the variables being studied in the trial affect women or
members of minority groups, as the case may be, differently than other
subjects in the trial. [28]
The statute also states that the exclusion of women and minorities is only to be allowed
under certain circumstances, such as when either the health of the participants or the
purpose of the research deems inclusion unacceptable, or if past research strongly refutes
the possibility of a difference in outcome or severity due to gender or race.

NIH Guidelines of 1994, Amended 2000 & 2001
In 1994, the National Institutes of Health published a set of guidelines mandating the
inclusion of women and minorities in clinical research, as directed by the NIH

Revitalization Act of 1993. Since that time, all clinical research funded by the NIH has
been required to meet these minimum standards. In addition to representation of women
and racial/ethnic minorities in clinical trials, the NIH Guidelines also require each
research proposal to include a description of outreach programs to recruit these
underrepresented groups. However, the “valid analysis” required by the Revitalization
Act is defined by the NIH as “an unbiased assessment,” [28] including randomization
into groups and use of unbiased outcomes evaluation and statistical analysis among
groups. The Guidelines do not require every NIH - funded clinical trial to have the
statistical power necessary to explore possible differences due to gender or race/ethnicity.
They also report that analyses should look for a “significant difference,” of public health
or clinical importance, rather than a “statistically significant difference.” [28]

The two later amendments to the NIH Guidelines, in 2000 and 2001 [29], were primarily
created to redefine the term “clinical trial” as well as the process of data collection on
race and ethnicity. Specifically, the NIH now mandates the use of racial and ethnic
categories as defined by the United States Office of Management and Budget.
Researchers are required to first ask participants to classify their ethnicity into one of two
categories: 1) Hispanic or Latino and 2) Not Hispanic or Latino. Participants should then
have the option of categorizing their race into one or more groups. These include:
American Indian/Alaska Native, Asian, Black/African-American, Native Hawaiian/Other
Pacific Islander, or Caucasian. This is the same process used during for the 2000 US
Census.

Race & Ethnicity: Definitions & Stress
It has been maintained that the NIH Guidelines described above were created in an
attempt to ensure that the science behind clinical trials is generalizeable to a larger
population, rather than due to political reasons or popular opinion. [30] It can be argued
that the use of race and ethnicity in clinical trials is important because double-blind
studies, in particular, may offer one of the few ways to display any potential ethnic and/or
cultural differences in mental illness and treatment without bias, or at least with
significantly decreased bias. However, along with a mandate to produce studies
containing larger numbers of minority subjects comes the question of the definition of
both race and ethnicity, as well as how to best approach analyses involving these
variables. In a 1996 special supplement, the Journal of Consulting & Clinical
Psychology published a number of articles regarding the implementation of the NIH
Guidelines, including two that addressed the concepts behind demographic factors such
as race and ethnicity. [31, 32] Beutler et al., in a review of articles published in three
journals between 1970 and 1993, reported that demographic variables such as race,
ethnicity, sex, gender, and age, were “not used consistently and lack empirical and
conceptual validity.” [31] They argue that these should be considered as constructs rather
than immutable characteristics, and as such, investigators should report the definitions
and explain the use of each term in clinical research. In addition, they specify that the
word ‘ethnicity’ should be used in lieu of ‘race’ whenever the implication of a cultural vs.
biological basis for the construct exists.

The potential for misuse is often cited as reason to be wary of considering race or
ethnicity in clinical trials. Science has a history of being used as justification for the
mistreatment and continued oppression of people of color. [33, 34] One potential reason
for the lack of minority representation in clinical studies and the lack of analysis of
potential effects of race or ethnicity is that investigators may lack experience with multicultural or underrepresented populations. As such, many may be wary of attempting to
interpret differences attributed to ethnicity, or believe that multiple different hypotheses
are required in order to address each racial or ethnic category. [32] When investigating
potential differences in outcomes based on ethnicity, however, an important consideration
is the role that minority status 5 may play in results. Past research has found that among
ethnic minorities in the United States, life experiences are shaped by minority status. [35]
in [32] Because of this, it may be important for clinical research investigators to include a
set of questions, or tools, to assess such issues including the amount stress encountered
by participants. The importance of this is highlighted by the fact that 60% to 70% of
adults who suffer from depression have been found to have undergone one or more
losses, or other life events rated as severely stressful, in the one year preceding onset of
the depressive episode. [3]

Moderators/Secondary Analyses
A moderator is defined as a variable that precedes treatment and is unchanging, at least
during the course of treatment. It has the potential to affect treatment outcomes, but is
uncorrelated to treatment. [36] Moderators are essential when attempting to assess the
5
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effectiveness of a particular treatment option, for example, as they can help identify
specific populations or sub-populations that may experience different treatment
outcomes. They “specify for whom and under what conditions an intervention works.”
[36] Mediators, on the other hand, may change during treatment (such as treatment
adherence or dosage), and have been shown to have a role in determining the mechanism
of action of treatments. [36, 37] The terms mediator and moderator are mutually
exclusive. The classification of a variable as a moderator or mediator is done through
secondary analyses, which increases the risk of type II errors while remaining at risk for
type I errors. [37] Researchers can determine which variables to explore as potential
moderators or mediators based on previous data or theory; these analyses are considered
to be methods of creating new hypotheses rather than testing them. [36] In addition, as
opposed to other types of research, the effect size is prioritized over the P value. A
moderate or large effect size points to the possibility of clinical differences that were
unable to reach significance due to limited power. Predictors are related to treatment
results, but in a non-specific way: they are not linked to treatment assignment, and are
uncontrolled. [37]

STATEMENT OF PURPOSE/HYPOTHESIS
Beginning with the assumption (required by the NIH) that racial diversity is important to
the generalizability of clinical trial outcomes, I hypothesize that all pediatric depression
and anxiety clinical trials will (1) include specific minority outreach plans as part of
recruitment; (2) include data on minority participation in the sample description; and (3),

include a moderator analysis specifically devoted to race/ethnicity. As a comparison,
race will be compared to gender and SES, two other important demographic variables.

There is more work to be done in the field of treatment for child & adolescent mood
disorders. It has been found that some pharmacological and therapy-based treatments can
be efficacious when treating youth, but it becomes important to design such treatments to
be as effective as possible. While generalizations and stereotypes can be dangerous,
differing beliefs about treatment may require physicians to better design outreach and
treatment methods to suit the particular population(s) with which they are working
(which may or may not differ based on demographic variables such as age,
socioeconomic status, and race). The aim of this literature review is to consider the trials
that have already been done in this area (reviewing the use of these demographic factors),
and define research areas of need in this field. The broad goal is to ensure that prevention
strategies and treatments for depression are able to be as valuable as possible.

METHODS
Literature Review
Published randomized controlled trials on the treatment of child and adolescent
depressive and anxiety disorders from 1994 through December 2005 were identified
using the Medline and PsychINFO databases. Search terms included depression,
dysthmia, bipolar, anxiety, separation anxiety, selective mutism, panic disorder, phobia,
child, and adolescent. Psychosocial and psychopharmacological treatment studies that
employed a control or a comparison condition were evaluable. Medline searches were

limited to the English language, with Randomized Controlled Trial as the publication
type, and to All Infant (birth to 23 months), Pre-School Child (2-5 years), Child (6-12
years), or Adolescent (13-18 years) for age. Because of the inclusion of age 18 under the
Adolescent group in Medline, many adult studies were recovered. These were excluded.
PsychINFO searches were also limited to the English language, with Clinical Trial as the
Form/Content Type, and Childhood (birth-12 years) or Adolescence (13-17 years).
Systematic reviews in peer-reviewed journals and the reference lists of identified trials
were used to retrieve additional articles. Studies conducted entirely or in part (i.e. one
site of a multi-site study) outside of the United States of America 6 were excluded due to
the use of US Census data as a comparison for racial representation. Those dealing with
Obsessive-Compulsive Disorder, Post-Traumatic Stress Disorder, Tourrette’s Syndrome,
and Trichotillomania were also excluded. Follow-up studies of randomized controlled
trials were included when they themselves were classified as RCT’s. However, to ensure
that no information was replicated, these follow-up studies were not factored into reviews
of recruitment strategies nor into the analysis of representation unless such information
was excluded from the original trial. In this case, the information from the first follow-up
study to report recruitment/demographic data was utilized.

The 37 original trials and 13 follow-up studies identified (See Tables 1 and 2) were then
reviewed for the extent to which race/ethnicity and other demographic factors were 1)
factored into recruitment strategies; 2) represented in the trial samples; and 3) included in
moderator analyses to determine the extent to which they may influence trial outcomes.
When possible, the treatment of race, gender, and socioeconomic status as demographic
6
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variables and potential moderators were compared. When looking at overall trends, we
have combined each individual minority grouping into one category, given the small
number of participants in each group.

Census Data
US Census Data was obtained from the US Census website <factfinder.census.gov>.
Inter-census population estimates were also obtained from this website. Both the 1990
and 2000 US Census (as well as population estimates) distinguish between race and
ethnicity; all participants were asked to report their race as well as whether or not they
considered themselves to be of Hispanic origin (Spanish, Hispanic, or Latino). In the
1990 Census, respondents were asked to identify their race within one of five categories:
“White,” “Black or African American,” “American Indian and Alaska Native,” “Asian,”
and “Native Hawaiian and Other Pacific Islander.” Of note, the 2000 Census included a
sixth grouping, “Some other race,” and also allowed each participant to select more than
one of these six categories when describing own race. Despite this, 98% of people
reported only one race. 97% of respondents who only reported themselves as “Some
other race,” are of Hispanic origin. [38]

When reporting Census information from 2000 or afterwards, we use “one race alone”
responses as an estimate for racial representation in the United States, with the
understanding that while this does not take into account ~2% of respondents, it better
allows for comparison across the years given that earlier respondents were not given the
option of choosing more than one racial category. Specifically, since NIH guidelines

include the use of Hispanic/Latino as a “minority group”, we use the “one race, not
Hispanic” data for the racial categories described above, and use “Hispanic, any race”
data to estimate the number of Hispanics/Latinos in the United States.

RESULTS
Recruitment Methods
One study [39], 2.7% of the total number of original trials, did not describe recruitment
methods used.

The majority of studies (78.4%) [40-68] reported that patients were recruited through
school referrals, media advertisements, referrals from health care providers, or a
combination of these three. Seven (18.9%) [69-75], however, differed in their approach.
Two [69, 72] recruited patients from consecutive inpatient admissions for depression and
bipolar disorder. These were the only trials in which participants were not recruited as
outpatients. In fact, many of the reviewed studies included recent or current inpatient
admission as part of their exclusion criteria.

The remaining five trials [70, 71, 73-75] instead screened out eligible participants from
larger previously defined populations (such as students in particular schools or HMO
members) that were not self-referred or referred by others. Four of these trials [34, 70,
73, 75] began with one or more schools, offering screening tests to discover potential
subjects and then randomizing identified students into treatment groups. Thompson et al
investigated suicide prevention methods by initially identifying students deemed at-risk

for dropping out of school from seven urban high schools in two school districts in the
Pacific Northwest, based on various criteria such as attendance and academic
performance. They then offered screening specific for suicide risk. While all four high
schools in one district were included, only three in the second district were selected. This
decision was based on “their geographic and demographic representation of that district’s
10 high schools.” Clarke et al. [70], Lamb et al. [73], and Weisz et al. [75] used a similar
strategy, identifying students with depression or “depressive symptomology” [73] from a
rural high school [73], 3 suburban high schools[70], and three elementary schools [75].
While the choice of high schools in Thompson et al was at partially explained, none of
the three other studies offered a comparison of their schools’ racial composition to that of
the geographic area in which they are located.

Clarke et al. [71], on the other hand, searched for depressed parents and children from an
initial sample of about 410,000 patient records from a Health Maintenance Organization
previously shown to be somewhat representative of the local population. They ended
with 88 participants.

Two studies, recruiting from outpatient clinics, specifically stated that they did so
“without regard to race, gender, or ethnicity.” [48, 68] In a follow-up article to the TADS
study, however, it is reported that part of the selection process for sites was based on the
“demographic composition” at the clinics. [76] None of the trials reviewed revealed
explicit attempts at recruiting women or minorities into the studies, although in both
studies by Mufson et al. [55, 67] the population was exclusively comprised of adolescents

referred to school-based health clinics in New York City, meaning that participants were
limited to students at those particular schools. The studies referred to the fact that the
schools were located in “urban, impoverished areas.” [67]

Representation
Six of the thirty-seven original studies (16.2%) did not report race or ethnicity in any way
(See Table 3). Of these, only one [59] had at least one follow-up RCT published [77] in
which the racial composition of participants was reported. Of the thirteen follow-up
studies themselves, five [78-82] did not report the representation of different racial
categories in the study population. However, all of these did have race reported in either
the original study or another follow-up series. The remaining eight reported race in some
way. [37, 76, 77, 83-87]

Ten of the initial studies (27.0%) failed to describe the specific race/ethnicity of
participants, instead forming two groupings: one comprised of Caucasians and the other
of ‘minorities’ or ‘other.’ While two of these [45, 46] had subsequent follow-ups
published, none of the seven follow-up trials included more detailed information.

Four studies [55, 56, 67, 74], or 10.8% of the total, reported equal or greater numbers of
minority participants as compared to Caucasians. Two studies [41, 85], 5.4%, reported
that 100% of the participants were Caucasian.

Overall, 3330 children and adolescents participated in these thirty-seven original clinical
trials. Of these, 3082, or 92.6% of the participants, took part in studies reporting race
and/or ethnicity. The majority of these young people described themselves as Caucasian
(n=2213, 66.5% of the total, 71.8% of those studies reporting race). 288 (8.6% of total,
9.3% of reporters), were African-American; 277 (8.3% total, 9.0% reporters) were
Latino; 89 (2.7% of total, 2.9% of reporters) were Asian/Pacific Islander, 18 (0.5% of
total, 0.6% of responders) were Native American, and 6 (0.2% of total & reporters)
classified themselves as “Mixed-Race”. In addition, 190 (5.7% total, 6.2% reporters )
were either grouped into an “other” category in those studies specifying specific
races/ethnicities, or were categorized as “minorities” in those studies choosing not to
specify race other than Caucasian. 248 of the 3330 total participants (7.4%) contributed
to those studies not reporting race/ethnicity in any way in the original publication. Of
these, however, 63 were participants in the Bernstein et al. [59] trial, for which a followup study detailing demographic data was published. [77] Therefore, the race and/or
ethnicity was not reported for 185 children and adolescents (5.6%) contributing to
published work. (see Table 3 and Figure 1)
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Figure 1. Minority Representation in Original Trials Reviewed
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The large (n > 100) studies, of which there were nine, accounted for over half (59.8%) of
the total participants. A greater percentage of these participants (70.9%) classified
themselves as Caucasian, African-Americans (12.1%), Asian (4.2%), and Native
American (0.9%). However, a lower percentage of subjects in the large studies consider
themselves to be Latino (6.1%) and Mixed-Race (0%). As compared to all original
studies, about the same proportion (5.8%) of participants were classified as minorities, or
considered themselves “Other.”

There were a larger number of studies conducted in the area of depression/bipolar (n=22)
than anxiety/phobic disorders (n=15). In addition, there were far more participants
(n=2336 vs. 994). 28.2% of participants in depression studies, and 21.1% of anxiety trial
subjects, classified themselves as minorities. 11.2% of the subjects’ race went unreported
in anxiety trials, vs. 5.9% in depression trials. In studies of psychotherapy interventions
only (21 studies with 2323 total participants), 29.3% of the children and adolescents were
minorities. Race was unreported for 5.6% of them. In trials that included at least one
branch testing pharmacotherapeutic options (16 studies, n=1007), race was unreported for
14.3% of subjects. 18.8% were minorities.

According to the 2000 US Census data, 69.4% of the US population defines themselves
as White or Caucasian (not Hispanic), 11.8% as Black or African-American, 12.5% as
Hispanic or Latino, and 3.7% as Asian, 0.6% as American Indian or Alaska Native, and
0.1% as Native Hawaiian or Pacific Islander. However, the yearly population estimates

from 1994 through 2005 show a fairly steady, if small, upward trend in terms of the
percentage of people classifying themselves as racial/ethnic minorities. (Figure 3)

There are three years, 1996, 1999, and 2001, in which the percentage of minorities
participating in reviewed clinical trials was greater than the percentage classifying
themselves as minorities in US Census estimations. In 1996, only two original trials were
reviewed, the larger of which (n=151) had a relatively large proportion of minorities,
about one third. The smaller study (n=31) consisted of about one quarter. In 1999, the
results were significantly affected by the fact that two of the four studies reviewed from
that year had greater numbers of minority participants than Caucasian participants.
Interestingly, one study of the four did not report race at all, and the remaining study
from 1999 was almost 40% minority. Similarly, in 2001, study with the largest sample
size reviewed, n=460, had a greater proportion of minority subjects than Caucasian
subjects.

Although both the number of randomized, double-blind trials in the field of child and
adolescent psychiatry as well as minority participation in these trials have generally
increased since 1994, there does not seem to be an obvious trend in minority
representation when studies are examined by year. This remains true when confidence
intervals are taken into account. (see Figure 2) Of the eleven years examined in this
review, only in four years did the proportion of minority participants approach or exceed
the proportion of minorities living in the United States.
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Figure 2. Minority Representation by Year (as Compared to US Census Data). UCI: Upper Confidence
Interval. LCI: Lower Confidence Interval

Moderator Analyses
Of the original studies reviewed, nine made no mention of whether there were pretreatment or randomization differences based on demographic variables. [41, 43, 45, 51,
53, 54, 61, 71, 75] Five, while discussing other demographic variables such as sex and
age, did not include race/ethnicity. [40, 46, 50, 70, 73] Twelve used general phrases such
as ‘no differences between treatment groups based on demographic variables” without
explicitly mentioning race. Of these studies, two did not report the race of the
participants. [48, 59] Eleven discussed race or ethnicity, primarily in order to ensure the
lack of pretreatment differences across groups, and/or between completers and noncompleters. Of these, Treadwell and Kendall reported an increased number of AfricanAmericans in the control group, and randomized to the wait list. Birmaher et al.
commented that there were no African-American males in the study population. [69] Of
note, every original study reviewed reported patient sex or gender along with age. One

study was noted to be entirely comprised of females; race was unreported in the trial. [61]
Fifteen reported some form of socioeconomic status (SES) or income.

Eleven original studies did not otherwise mention race or ethnicity in the “Results” or
“Discussion” (or equivalent) sections at all. Eight pointed out that more ethnically
diverse samples were necessary, or cited “ungeneralizability” as a study weakness.
Interestingly, the authors of one of these trials discussed that the study might not be
applicable to the larger population due to the large numbers of Latino females in the
sample. [55] Five either explored the possibility of race or ethnicity having an interaction
or moderating effect, and/or discussed race or ethnicity as it pertained to treatment
outcomes. [42, 44, 47, 56, 75] Of these, three (8.1%) explicitly explored the possibility of
ethnicity as a moderator through analysis of variance (ANOVA) testing; it was found to
have no moderating role in any. The other two point out that “comparable effectiveness”
[47]is suggested across demographic lines.

Of the thirteen follow-up studies, six considered ethnicity when attempting to determine
whether there were randomization or completer/non-completer differences. Three
(23.1%) were written to look for possible moderators and mediators in depression [81,
85] and anxiety [37]. In all three analyses, no demographic moderators were found. In
the RUPP article, however, race/ethnicity was initially found to have an effect size of
0.47 (with 0.5 being considered a moderate effect size).

Further investigation showed

that neither 3-way (p=0.07) nor 2-way (p=0.33) interactions were statistically significant.
In addition, the TADS follow-up study looked at demographic characteristics, comparing

their population to previous work. The authors specifically mentioned the possibility of
performing moderator and mediator analyses in the future, due to their large and diverse
study population.

DISCUSSION
Recruitment Methods
Few trials demonstrate any directed attempts during recruitment to ensure racial/ethnic
diversity. In those trials that screened out participants from a larger population, the
choice of school, hospital, or HMO location proved to affect the diversity of the study
sample population. For instance, in the two Mufson et al studies [55, 67], school clinics
located within public schools in New York City were used as the site of the research,
resulting in a high percentage of minorities, particularly Latinos. In the Thompson et al.
study, the location of the seven urban high schools examined, in the Pacific Northwest,
allowed for a greater number of minorities, particularly Asian/Pacific Islander and Native
American. The study noted that the contributing schools had minority representations
ranging from 34% to 60%. On the other hand, the Clarke et al. [71] trial noted that it
screened the entire population of an HMO, also located in the northwest, that was
representative of the surrounding area. Despite this, the final result was a sample 90% of
which was Caucasian. It was not noted whether or not the HMO was located in an urban
or rural area. Both studies that recruited directly from inpatient hospitalization ended
with similar numbers of minority representation; Birmaher et al 1998 had a minority
representation of 11.1%, while DelBello et al. was comprised of 16.7% minority
participants. Both fell below the average for all studies reviewed. Of note, one multi-site

trial [68] documented, in a follow-up study also reviewed, that demographic make-up of
potential sites played a role in their selection.

It is important to investigate the trials that ended with a greater number of minority
participants, as well as those that ended with none, to assess whether recruitment
methodology may have played a part in representation outcomes. Again, four studies had
equal or greater numbers of minorities. Of these, only Silverman et al. 1999 utilized the
most common form of recruitment, referrals from a variety of sources including schools
and health professionals. The remaining three [55, 67, 74] recruited from school-based
clinics based in urban public schools, greatly affecting the potential trial population from
the start. Given the likelihood of any public school to approach or exceed minority
representation on a local level, one feasible option for investigators seeking to augment
the proportion of minorities in their trial seems to be to increase involvement . However,
there are drawbacks as well, such as the possible restrictions placed on research by school
districts.

The only trial reviewed with 0% minority representation was Graae et al. 1994, a study
that reported the use of clinic and school sources along with newspaper ads as
recruitment methods. Of the ten reviewed trials that utilized advertisements in any way,
four did not report race/ethnicity. Overall, 196 of the 1036 total participants (18.9%) in
these studies classified themselves as minorities. Of the three trials that reported only
using methods of advertisements 7 as recruitment tools, none reported the race of their

7

Local ads and/or announcements sent to schools/clinics

subjects. Three studies used advertisements as part of a large variety 8 of recruitment
methods; in these, 27.0% of the participants were minorities. Given the differences in
attitudes toward medicine and medical research experienced by persons of different
ethnic backgrounds, it is possible that ad placement, while potentially reaching a great
number of people, may be too impersonal a method to sufficiently reach a minority
population. Interestingly, one study [45] reported that participants recruited via clinic
referral were less likely to respond to psychotherapy than those recruited by
advertisement. This was attributed to differences in hopelessness scores. The trial did
not indicate whether method of recruitment was associated with race or ethnicity in any
way.

As mentioned above, there are numerous examples of the ways in which race can play a
role in the amount of trust a prospective study participant has in medical researchers
and/or medical trials, and a number of historical reasons for this disparity. Such a lack of
trust may make it significantly more difficult for investigators to obtain ethnically diverse
samples, which is vital when attempting to tease out the possible role that race may play
in treatment outcomes. However, this difficulty cannot be an excuse, especially given the
emphasis in the NIH Guidelines on minority outreach methodology. Targeted recruiting
methods exist; it is the role of researchers to ensure that their samples are representative.
Training and increased education on this subject are essential. The NIH has published an
“Outreach Notebook” as a tool to assist researchers with recruitment of minority
participants. [88] In addition, there have been other series, such as the Journal of
Consulting and Clinical Psychology’s (JCCP) post-NIH Guideline supplemental issue in
8

Four or more different methods used, including advertisements

1996. The articles included addressed a variety of issues surrounding the guidelines and
their implementation, including the importance of recruitment methods.

In one article, the outreach methods utilized in a sizeable study of psychiatric inpatients
in a low-income, urban area are described. [34] The authors describe a four-pronged
approach to the recruitment of African-Americans with schizophrenia or mood disorders.
Through a combination of a community partnership with a local mental health clinic,
emphasis on interviewer selection and interviewer training, and an exploration of the role
of cultural sensitivity through an assessment of ethnic matching 9 , they were able to
recruit a sizeable population of African-American patients. Of note, they found that
ethnic matching did not affect refusal or completion rates; patients were more likely to
refuse or drop out based on type of mental illness. [34] This is positive news for
investigators interested in recruiting greater numbers of minority participants, particularly
since it seems possible that the focus on interviewer training may have helped to
overcome potential barriers based on race or ethnicity. However, it may also be valuable
to recruit an increased number of minority researchers, given the fact that both the IOM
and Surgeon General’s Report state that minority medical professionals are more likely to
work in areas comprised of minorities, and that in general, patient trust may be increased
with doctors or researchers of the same racial/ethnic background.

Representation
Despite the fact that the majority do report in some way the racial/ethnic breakdown of
their sample population, approaches to this process, as well as the level of specificity,
9

Matching recruiter/interviewer and patient by race, ethnicity, cultural background, or a combination

varies from study to study. The majority of patients participating in these studies are
classified as Caucasian. Overall percentages of African-Americans, Latinos/Hispanics,
and Asian/Pacific Islanders participating in trial samples are lower than those reported in
the US population as of the 2000 Census. While the proportion of Native Americans
participating in these studies is equal to the proportion in the United States, only one
reviewed trial (Thompson et al.) included any Native American participants. Looking at
yearly US population estimates by race and ethnicity since 1994, there has been a small
but steady increase in the percentage of the US population that is comprised of people
self-identifying as minorities. In 1994, 26.0% of the US population classified themselves
as minorities, while in 2004 that number was 31.1%.

This rise is primarily due to the proportion of Hispanics and Latinos in the country, which
increased from 10% in 1994 to 14.2% in 2004. Given this fact, it becomes even more
important consider the role of culture and language in treatment outcomes research.
Many reviewed studies included language other than English as an exclusion factor,
which may have decreased the number of minority patients able to participate,
particularly in the Latino and/or Asian categories. The Spanish language is spoken by
approximately 30 million US citizens over the age of 5. [89] The United States hosts the
5th largest Spanish-speaking community in the world. [89] One recent study not included
in this review, 10 by Rossello and Bernal, did begin to address some of these issues. [90]
With a study population that was 100% Hispanic/Latino, and Spanish-language
interventions available, the trial referenced their use of culturally sensitive therapy. One
reviewed study [67] allowed primarily Spanish-speaking students to participate in two
10

Due to its location in Puerto Rico

sites (out of five); two others mentioned and briefly described their use of culturally
sensitive therapy. [56, 57] Of note, these two trials had study populations comprised of
44.5% minorities, much higher than that of the US population. While shown to be
effective in a number of trials, cognitive behavioral therapy (CBT) has also been shown
to less efficacious in community samples than in trials. (Weersing and Weisz 2002) The
inclusion of greater numbers of minority participants in studies, along with the increased
use of ‘culturally sensitive’ therapy, may serve to better allow the transfer of CBT and
other therapies in particular from the controlled trial to the clinic.

Moderator Analyses
Three of the original studies reviewed, 8.1%, specifically included ethnicity as a potential
moderator as part of their analyses. In addition, there were three follow-up studies (23%)
designed to search out the role of various demographic and other variables as moderators
and mediators. Among the other studies that explored possible effects of race or ethnicity
on treatment outcome, many discussed trends rather than reporting means. One followup study, citing their large and diverse sample size, did discuss future moderator and
mediator analysis. [76] However, the majority of studies reviewed do not have the sample
sizes or minority representation required to accurately assess the possibility of race or
ethnicity as a moderator.

Limitations
Due to the variety of disorders and treatment options reviewed, a meta-analysis was
unable to be done. Instead, a literature review, a less statistically rigorous method, was

performed on these trials. Because of this, it is impossible to estimate the role that
race/ethnicity may play in child and adolescent depression and anxiety based on current
outcomes research. Rather, this review serves to look at the research being done in this
area, with an emphasis on the way that race and ethnicity are incorporated into outreach
strategies, reporting methods, and analysis.

The methods used to identify trials, including Medline and PsychInfo searches as well as
reviewing reference lists, may not have been all-inclusive. Some trials may have been
missed. In addition, some of the exclusion criteria used in this review, particularly the
limitation to those studies performed entirely within the United States, served to
eliminate some important large and/or multi-site studies, such as the Rosselló and Bernal
trial mentioned above as well as a 2004 multi-center trial investigating the use of
paroxetine in Social Anxiety Disorder (Wagner et al.), to name only a few. Another
important exclusion criterion was disorders such as OCD and PTSD, which may have
overlooked trials that did include considerable numbers of minority participants and/or
performed moderator analyses using race and ethnicity.

Future Research Needs
Based on this review, it seems clear that additional work needs to be done in order to
correctly assess the existence of a relationship between race/ethnicity and treatment
outcomes in child and adolescent trials in depression and anxiety. Given the differences
between study populations and the US population with regard to race and ethnicity, the
generalizability of many of the trials reviewed is uncertain. It is also unclear that

outreach methods currently being used are sufficient to recruit large numbers of minority
participants. It is possible that more training is necessary for investigators in order to
achieve adequate sample sizes as well as report accurately using NIH guidelines. Once
this is achieved, it will become possible for a greater number of studies to investigate the
possible role that race and/or ethnicity may play in the pediatric depression and anxiety
trials.

Conclusions
There has been significant improvement in the inclusion of minorities in randomized
controlled trials in the field of child and adolescent depression. However, minority
representation in trials reviewed between 1994 and 2005 (inclusive) still lags behind US
Census Data, both in average and also when compared on a yearly basis. There is no
apparent trend when minority trials are aggregated by year; that is, as opposed to US
Census data over the past 11 years, there has been no steady increase or decrease of
minority representation in these clinical trials. Rather, it seems that some trials,
particularly the larger multi-site studies along with those that are comprised of over 50%
minority participants, have sizeable effects on the percentage of minority participants in a
given year. Inclusion of minorities in clinical trials may be positively influenced by a
shift in the focus of recruitment methods. The more universal consideration of
demographic makeup during clinical site selection may prove to increase the number of
minority participants in RCT’s. Also, additional investigator training and/or sharing of
“best practices” may encourage the use of targeted recruitment methods. As the
proportion of minority subjects in child and adolescent depression and anxiety trials

increases, it will become possible for moderator analyses to be performed, so as to
determine whether race or ethnicity have an affect on treatment outcomes or effectiveness
of treatment options.
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CBT
GCBT, GCBT
+ parent
group; +
"Booster"
sessions
IPT

47
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0.0%
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46.4%
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38.3%

61.7%
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35.8%
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0.0%
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22.0%
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0.0%
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0.0%
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10.8%
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0.0%
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CBGT
CBT
(Comorbidity)
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0.0%
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0.0%
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usual care
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DelBello et al
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Birmaher et
al
Mufson et al
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0.0%
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0.0%

16.7%
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Anxiety
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Fluoxetine
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Fluoxetine,
Both
Citalopram

74
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28.6%
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0.0%
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0.0%

2.7%
0.0%

0.0%
0.0%

439
174
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77.0%

12.5%
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4.8%
23.0%

Depression
Depression

